Michael J Mauro
Overview
Explore the profile of Michael J Mauro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
2530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes J, Hughes T, et al.
Leukemia
. 2023 Jan;
37(3):617-626.
PMID: 36717654
Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase...
12.
Atallah E, Mauro M, Hochhaus A, Boquimpani C, Minami Y, Maheshwari V, et al.
J Cancer Res Clin Oncol
. 2023 Jan;
149(9):6247-6262.
PMID: 36707445
Purpose: The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML) is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML failing ≥ 2 lines of treatment, partly...
13.
Sweet K, Cortes J, Apperley J, Mann M, Mauro M, Oehler V, et al.
Clin Cancer Res
. 2022 Dec;
29(12):2179-2183.
PMID: 36547666
The FDA has an accelerated approval program for drugs that have been identified as promising treatments for serious conditions when the available data suggest that the benefits outweigh the foreseeable...
14.
Brummendorf T, Cortes J, Milojkovic D, Gambacorti-Passerini C, Clark R, le Coutre P, et al.
Leukemia
. 2022 Jun;
36(7):1825-1833.
PMID: 35643868
This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five...
15.
Flynn K, Atallah E, Lin L, Shah N, Silver R, Larson R, et al.
Haematologica
. 2022 May;
107(11):2641-2649.
PMID: 35511672
For patients with optimally treated chronic myeloid leukemia (CML), discontinuation of tyrosine kinase inhibitor (TKI) therapy can lead to treatment-free remission. In previous trials, TKI discontinuation has been associated with...
16.
Mauro M
Hematology Am Soc Hematol Educ Program
. 2021 Dec;
2021(1):113-121.
PMID: 34889360
Beginning with imatinib and now spanning 6 oral, highly active, and mostly safe agents, the development of specific targeted therapy for patients with chronic myeloid leukemia (CML) has created a...
17.
Kozak K, Ouyang L, Derkach A, Sherman A, McCall S, Famulare C, et al.
Leukemia
. 2021 Nov;
35(12):3578-3580.
PMID: 34741117
No abstract available.
18.
King A, Weis T, Derkach A, Ball S, Pandey M, Mauro M, et al.
Am J Hematol
. 2021 Oct;
97(1):E7-E10.
PMID: 34674293
No abstract available.
19.
Schoenbeck K, Atallah E, Lin L, Weinfurt K, Cortes J, Deininger M, et al.
J Natl Cancer Inst
. 2021 Sep;
114(1):160-164.
PMID: 34491344
Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information...
20.
Rea D, Mauro M, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al.
Blood
. 2021 Aug;
138(21):2031-2041.
PMID: 34407542
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate...